---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-033793"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2026-02-02T23:59:59+00:00"
generated_at: "2026-05-16T05:32:32.350597+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lexicon raises ~$94.6M via public offering and private placements; Invus to hold ~51% post-conversion

## Summary
- Public offering of 32M shares at $1.30/share raises ~$41.6M gross; underwriters have 30-day option for 4.8M more shares.
- Concurrent private placement: 22.4M common shares to Invus at $1.30 for $29.12M; also 184,366 Series B Convertible Preferred shares at $65 each (~$11.98M) convertible into 9.2M common shares.
- Additional private placement: Invus buys 182,779 more preferred shares at $65 each for ~$11.88M, convertible into 9.1M common shares; total preferred convertible into ~18.3M common shares.
- After conversion of preferred and stockholder approval to increase authorized shares, Invus entities will hold about 51% of outstanding common stock.
- Net proceeds to fund continued R&D of drug candidates and for working capital and general corporate purposes.

## SEC filing metadata
- accession: 0001193125-26-033793
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2026-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 5.03, 3.02, 3.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000119312526033793/0001193125-26-033793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000119312526033793/d32395d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-033793
- JSON: https://secwatch.observer/filing/0001193125-26-033793.json
- Plain text: https://secwatch.observer/filing/0001193125-26-033793.txt

## Source-grounded claims
- claim_id: c41c2e1bd6b403e999bffa594e060c30832c908d
  claim: LEXICON PHARMACEUTICALS, INC.: Filing of Certificate of Designations for Series B Convertible Preferred Stock, including terms for automatic conversion conditioned on stockholder approval of a new charter increasing authorized common shares (effective 2026-02-02).
  evidence_excerpt: On February 2, 2026, in connection with the Preferred Private Placement, the Company filed with the Secretary of State of the State of Delaware to be effective upon filing the Certificate of Designations of Series B Convertible Preferred Stock of the Company (the “ Certificate of Designations ”), in the form approved and adopted by the board of directors of the Company, which sets forth the terms of the Preferred Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1062822/000119312526033793/0001193125-26-033793-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.